Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

To treat pelvic nodes or not? Greater testicular scatter does not explain the results of randomized trials.

Roach M 3rd, Lawton CA, Chen J.

J Clin Oncol. 2010 Sep 1;28(25):e450-2. doi: 10.1200/JCO.2010.28.3010. Epub 2010 Jun 21. No abstract available.

PMID:
20567007
2.

To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials?

King CR, Kapp DS.

J Clin Oncol. 2009 Dec 20;27(36):6076-8. doi: 10.1200/JCO.2009.24.3808. Epub 2009 Oct 26. No abstract available.

PMID:
19858377
3.

Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials.

Roach M 3rd.

J Clin Oncol. 2008 Aug 1;26(22):3816-7; author reply 3817-8. doi: 10.1200/JCO.2008.17.9879. No abstract available.

PMID:
18669477
4.

Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.

Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nürnberg N, Schour L, Martinez A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1474-82. Epub 2005 Jun 20.

PMID:
15964706
5.
6.

[Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].

Matveev BP, Bukharkin BV.

Urologiia. 2001 Nov-Dec;(6):20-1. Russian. No abstract available.

PMID:
11785074
7.

Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.

Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA.

Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):567-74.

PMID:
10701735
8.

Androgen deprivation therapy for prostate cancer.

Bahnson R.

J Urol. 2007 Oct;178(4 Pt 1):1148. Epub 2007 Aug 14. No abstract available.

PMID:
17698142
9.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
10.

Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.

Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R.

J Urol. 2008 Oct;180(4):1438-43; discussion 1443-4. doi: 10.1016/j.juro.2008.06.029. Epub 2008 Aug 16.

PMID:
18710743
11.

Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.

Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):85-92. doi: 10.1016/j.ijrobp.2007.12.041. Epub 2008 Mar 20.

PMID:
18355982
12.

[Reevaluation of MAB therapy and progress of endocrine therapy].

Klotz L, Payne H, Gillatt D, Keane T, Morris C, Akaza H, Hirao, Akakura K, Fukagai T.

Gan To Kagaku Ryoho. 2005 May;32(5):705-28. Review. Japanese. No abstract available.

PMID:
15934164
13.

[Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].

Bolla M, Fourneret P, Descotes JL.

Bull Cancer. 2008 Dec;95(12):1213-8. doi: 10.1684/bdc.2008.0755. Review. French.

14.

Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy.

Zietman AL, Shipley WU.

Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):245-6. No abstract available.

PMID:
9069292
15.
16.

Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.

Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R.

J Urol. 2007 Mar;177(3):916-20.

PMID:
17296375
17.

Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.

Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV.

Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):931-9.

PMID:
9276357
18.

Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.

Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):695-701.

PMID:
15708247
19.

Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients.

Spiotto MT, Hancock SL, King CR.

Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):54-61. Epub 2007 Apr 24.

PMID:
17459606
20.

Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?

Guckenberger M, Baier K, Richter A, Vordermark D, Flentje M.

Radiat Oncol. 2008 Jan 11;3:3. doi: 10.1186/1748-717X-3-3.

Supplemental Content

Support Center